Momelotinib: all 21 studies that test it

Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeNot yet recruitingNCT07569081Phase 2/3
• Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingNCT07498205Phase 4
• Momelotinib During and After HCT in MyelofibrosisRecruitingNCT07104799Phase 1
• Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaRecruitingNCT07071155Early Phase 1
• A Study of Momelotinib in Participants With Low-risk Myelodysplastic SyndromeRecruitingNCT06847867Phase 2
• Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingNCT06517875Phase 2
• A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingNCT06235801Phase 1/2
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3Results posted
• Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)CompletedNCT02515630Phase 2Results posted
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2Results posted
• Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFCompletedNCT02101268Phase 3Results posted
• Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02101021Phase 3Results posted
• Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisCompletedNCT01969838Phase 3Results posted
• Extended Access of Momelotinib in Adults With MyelofibrosisActive, not recruitingNCT03441113Phase 2
• Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
• Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal AdenocarcinomaTerminatedNCT02244489Phase 1
• Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02206763Phase 1
• Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
• Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
• Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT01236638Phase 2
• Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)CompletedNCT00935987Phase 1/2

← Momelotinib overview